Form 4: IN8BIO CEO William Tai-Wei Ho Awarded Stock Options
SEC Form 4 Filing
IN8BIO's CEO, William Tai-Wei Ho, received a retention award in the form of stock options to purchase 500,000 shares of common stock.
Summary
- William Tai-Wei Ho, the President and CEO of IN8BIO, INC., was granted an employee stock option on September 4, 2024.
- The option allows him to purchase 500,000 shares of IN8BIO's common stock at an exercise price of $0.47 per share.
- The options vest in installments: 25% on March 4, 2025, 25% on September 4, 2025, and 50% on March 4, 2026, contingent upon continued service.
- The options expire on September 4, 2034.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and signals confidence in the CEO's leadership and the company's future prospects. There are no immediate negative implications.
Positives
- The stock option grant serves as a retention incentive for the CEO, aligning his interests with the long-term success of the company.
- The vesting schedule encourages continued service and commitment from the CEO.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives. The size and vesting schedule of the grant are typical for a company of IN8BIO's size and stage of development.
Comparison to Industry Standards
- Comparing IN8BIO's executive compensation to similar biotech companies like Celldex Therapeutics or Ziopharm Oncology, stock option grants are a standard component of executive pay.
- The vesting schedule of IN8BIO's options is also in line with industry norms, typically ranging from 3 to 4 years with cliff or graded vesting.
Stakeholder Impact
- Shareholders: The stock option grant could potentially dilute existing shareholders if the options are exercised.
- Employees: The grant could boost employee morale by demonstrating the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 09/04/2024 | Date of the stock option grant. |
| 03/04/2025 | 25% of the options vest. |
| 09/04/2025 | Another 25% of the options vest. |
| 03/04/2026 | Remaining 50% of the options vest. |
| 09/04/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.